Common treatment options for myelodysplastic syndromes include symptomatic supportive therapy, combination chemotherapy, and bone marrow transplantation therapy. Myelodysplastic syndrome is a hematologic malignancy in which normal hematopoiesis of the bone marrow is suppressed, accompanied by pathological hematopoiesis of the bone marrow, with a high risk of transformation to acute leukemia. Patients with myelodysplastic syndromes often exhibit decreased blood counts, including anemia, leukemia, and decreased platelet counts. For patients with severe anemia (hemoglobin <60g/L) and severely reduced platelet count (<20*10^9/L), transfusion of isohematopoietic red blood cells and single platelet collection is required to improve the symptoms of anemia and raise the platelet count. For patients with accompanying infections (lung infections, etc.), active anti-infection treatment is required. In addition to supportive treatment, drugs such as decitabine, azacitidine, cytarabine, etc. can be used in combination with chemotherapy; with active symptomatic supportive treatment as well as chemotherapy, bone marrow transplantation is also feasible when necessary. It is recommended that the patient go to the Department of Hematology in time, and the specialist will formulate an individualized treatment plan according to the patient's specific condition.